藥明生物(02269.HK)股價異動 擬不超5億美元總價格購回股份
格隆匯12月16日丨藥明生物(02269.HK)發佈公吿,公司已得悉公司股份於2021年12月15日出現股價及成交量不尋常波動。公司確認,其並不知悉任何根據香港法例第571章證券及期貨條例第XIVA部須予披露的資料。作為提供全方位端到端解決方案的合同定製研發生產服務企業(CDMO),公司幫助全球合作伙伴發現、開發及生產生物藥,造福廣大病患。
公司謹此強調,其在全球各個運營基地嚴格遵守適用的法律法規,且業務運營一切正常。截至該公吿日期,公司並不知悉任何可能對業務運營造成重大不利影響的監管制度的變動。公司將繼續致力賦能其合作伙伴,並對未來持續高速增長充滿信心。
根據公司股東於股東周年大會上通過的決議,公司董事獲授予一般授權,以購回不超過公司於2021年6月16日已發行股份總數10%的股份(即不超過合共4.233億股股份)。2021年12月16日,董事會已議決動用購回授權,以不時在公開市場上以不超過5億美元總價格購回股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
![](/hk/assets/image/code.84ab0b.png)
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.